Table 2.
Comparative univariate survival analysis the UTUC patients.
| Univariate analysis | OS | DFS | BRFS | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Group | |||||||
| ≤ 90 days | 1 | 1 | 1 | ||||
| > 90 days | 1.425 (0.883, 2.298) | 0.147 | 1.555 (0.903, 2.678) | 0.112 | 0.920 (0.580, 1.459) | 0.724 | |
| Sex | |||||||
| Male | 1 | 1 | 1 | ||||
| Female | 0.926 (0.730, 1.175) | 0.527 | 0.891 (0.674, 1.178) | 0.419 | 0.488 (0.400, 0.596) | <0.001** | |
| Age | |||||||
| <70 | 1 | 1 | 1 | ||||
| ≥70 | 1.915 (1.510, 2.428) | <0.001** | 1.368 (1.035, 1.809) | 0.028* | 0.929 (0.760, 1.137) | 0.475 | |
| ECOG performance status | |||||||
| 0 | 1 | 1 | 1 | ||||
| 1 | 1.336 (0.993, 1.797) | 0.056 | 1.258 (0.917, 1.725) | 0.155 | 1.124 (0.885, 1.426) | 0.339 | |
| 2 | 3.641 (2.427, 5.462) | <0.001** | 1.797 (1.071, 3.016) | 0.026* | 1.259 (0.815, 1.947) | 0.300 | |
| CCI | |||||||
| 0 | 1 | 1 | 1 | ||||
| ≥1 | 1.722 (1.270, 2.335) | <0.001** | 1.074 (0.776, 1.486) | 0.666 | 0.845 (0.676, 1.055) | 0.137 | |
| Tumor size | |||||||
| <1cm | 1 | 1 | 1 | ||||
| ≥1 & < 2 cm | 0.927 (0.615, 1.398) | 0.717 | 0.765 (0.450, 1.299) | 0.321 | 0.806 (0.587, 1.109) | 0.185 | |
| ≥2 & < 3 cm | 1.095 (0.733, 1.637) | 0.657 | 1.405 (0.869, 2.270) | 0.166 | 0.900 (0.656, 1.233) | 0.511 | |
| ≥ 3cm | 1.132 (0.780, 1.643) | 0.514 | 1.396 (0.889, 2.193) | 0.147 | 0.744 (0.553, 1.002) | 0.052 | |
| Tumor location | |||||||
| Renal pelvis | 1 | 1 | 1 | ||||
| ureter | 1.337 (1.029, 1.737) | 0.030* | 1.442 (1.053, 1.976) | 0.023* | 1.048 (0.837, 1.312) | 0.684 | |
| Renal pelvis + ureter | 1.261 (0.903, 1.760) | 0.174 | 1.627 (1.121, 2.363) | 0.010* | 1.346 (1.037, 1.748) | 0.025* | |
| Preoperative hydronephrosis | |||||||
| No | 1 | 1 | 1 | ||||
| Yes | 1.393 (1.076, 1.802) | 0.012* | 1.332 (0.992, 1.789) | 0.057 | 0.871 (0.713, 1.065) | 0.177 | |
| Lymphovascular invasion | |||||||
| No | 1 | 1 | 1 | ||||
| Yes | 1.766 (1.318, 2.368) | <0.001** | 2.207 (1.607, 3.032) | <0.001** | 1.025 (0.780, 1.348) | 0.858 | |
| Surgical margin | |||||||
| No | 1 | 1 | 1 | ||||
| Yes | 3.235 (1.810, 5.781) | <0.001** | 3.241 (1.759, 5.970) | <0.001** | 0.640 (0.265, 1.548) | 0.322 | |
| Pathological stage T | |||||||
| pTis/pTa/pT1 | 1 | 1 | 1 | ||||
| pT2 | 1.261 (0.928, 1.715) | 0.139 | 2.204 (1.507, 3.224) | <0.001** | 0.908 (0.700, 1.178) | 0.467 | |
| pT3 | 1.672 (1.263, 2.213) | <0.001** | 3.256 (2.319, 4.571) | <0.001** | 1.063 (0.841, 1.344) | 0.607 | |
| pT4 | 5.401 (2.511, 11.618) | <0.001** | 6.200 (2.477, 15.518) | <0.001** | 0.000 (0.000), | 0.926 | |
| Pathological stage N | |||||||
| pN0 | 1 | 1 | 1 | ||||
| pN+ | 1.238 (0.588, 2.604) | 0.574 | 2.389 (1.235, 4.622) | 0.010* | 0.627 (0.290, 1.355) | 0.235 | |
| pNx | 1.025 (0.757, 1.388) | 0.872 | 0.964 (0.689, 1.349) | 0.831 | 1.100 (0.863, 1.403) | 0.441 | |
| Cell Type | |||||||
| UC | 1 | 1 | 1 | ||||
| Not UC | 1.051 (0.652, 1.695) | 0.839 | 1.043 (0.606, 1.796) | 0.879 | 0.624 (0.389, 1.002) | 0.051 | |
| Adjuvant systemic therapy | |||||||
| No | 1 | 1 | 1 | ||||
| Yes | 0.764 (0.534, 1.095) | 0.142 | 1.082 (0.754, 1.553) | 0.668 | 0.778 (0.588, 1.031) | 0.081 | |
Cl, confidence; HR, hazard ratio; OS, overall survival; DFS, disease-free survival; BRFS, Bladder Recurrence-free survival; ECOG, Eastern Cooperative Oncology Group; CCI, Charlson Comorbidity Index
* < 0.05, ** < 0.01